• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Discovery and validation of drug targets for tumour angiogenesis.
【24h】

Discovery and validation of drug targets for tumour angiogenesis.

机译：发现和验证用于肿瘤血管生成的药物靶标。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The formation of blood vessels is a key process in the progression of solid tumours, providing the means for tumour growth and metastasis. A number of drugs are currently being developed to exploit inhibition of angiogenesis in the therapy of cancer. An even greater number of genes that are regulated in models of in vitro angiogenesis have been identified. These genes present potential drug targets for the development of novel, more efficient, drugs that will enable the judicious design of drug cocktails that may be able to account for the many different cancer pathologies and their drug resistance properties. Dealing with the validation of hundreds of potential angiogenesis drug targets requires the utilisation of experimental technology platforms that enable concomitant and dynamic target selection filtering and validation. Such platforms should act as a funnel-like medium-to-low throughput processes that enable the sequential short-listing of hundreds of candidates culminating in the selection of only a small number of well-validated targets that are manageable by drug screening regimes.
机译：血管的形成是实体瘤进展中的关键过程，为肿瘤的生长和转移提供了手段。当前正在开发许多药物来利用抑制血管生成来治疗癌症。已经鉴定出在体外血管生成模型中受调控的更多基因。这些基因为开发新型，更有效的药物提供了潜在的药物靶标，这些药物将能够明智地设计药物混合物，从而可以解释许多不同的癌症病理及其耐药特性。处理数百种潜在血管生成药物靶标的验证需要利用能够同时进行动态靶标筛选和验证的实验技术平台。此类平台应充当漏斗状的中低吞吐量流程，使依次筛选的数百名候选人成为最终候选人，最终只能选择可通过药物筛选制度管理的少数经过充分验证的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号